TW370461B - Use of cross-linked hemoglobin in treating subarachnoid hemorrhage - Google Patents

Use of cross-linked hemoglobin in treating subarachnoid hemorrhage

Info

Publication number
TW370461B
TW370461B TW085107552A TW85107552A TW370461B TW 370461 B TW370461 B TW 370461B TW 085107552 A TW085107552 A TW 085107552A TW 85107552 A TW85107552 A TW 85107552A TW 370461 B TW370461 B TW 370461B
Authority
TW
Taiwan
Prior art keywords
cross
subarachnoid hemorrhage
linked hemoglobin
treating subarachnoid
hemorrhage
Prior art date
Application number
TW085107552A
Other languages
English (en)
Inventor
Kenneth E Burhop
Daniel J Cole
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of TW370461B publication Critical patent/TW370461B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW085107552A 1995-04-10 1996-06-24 Use of cross-linked hemoglobin in treating subarachnoid hemorrhage TW370461B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41920995A 1995-04-10 1995-04-10

Publications (1)

Publication Number Publication Date
TW370461B true TW370461B (en) 1999-09-21

Family

ID=23661264

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085107552A TW370461B (en) 1995-04-10 1996-06-24 Use of cross-linked hemoglobin in treating subarachnoid hemorrhage

Country Status (8)

Country Link
US (1) US5854210A (zh)
EP (1) EP0767675A4 (zh)
JP (1) JPH10501823A (zh)
AU (1) AU693354B2 (zh)
NO (1) NO965247L (zh)
TW (1) TW370461B (zh)
WO (1) WO1996032130A1 (zh)
ZA (1) ZA962843B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017289A1 (en) * 1996-10-21 1998-04-30 Baxter International Inc. Therapeutic use of hemoglobin to treat head injury
KR100281083B1 (ko) * 1998-01-23 2001-02-01 서평원 이동데이터단말기간무선데이터통신방법
DE10220992A1 (de) * 2002-05-11 2003-12-04 Sanguibiotech Ag Verwendung eines oder mehrerer Sauerstoffträger, ausgewählt aus Hämoglobin, Myoglobin und Derivaten hiervon zur Behandlung einer Organfunktionsstörung infolge eines akuten Versorgungsmangels und zur Behandlung/Vermeidung einer Gewebeschädigung infolge einer solchen Störung
AU2003234944A1 (en) * 2002-08-27 2004-03-18 Bayer Healthcare, Llc Methods of Determining Glucose Concentration in Whole Blood Samples
EP2435387A4 (en) * 2009-05-26 2013-03-20 Univ Duke PROCESS FOR PROVIDING NERVE PROTECTION THROUGH THE USE OF PORPHYRINES
US20120308985A1 (en) * 2011-04-21 2012-12-06 Streck, Inc. Immature Reticulocyte Fraction Reference Control and Related Methods
US9244085B2 (en) * 2011-11-22 2016-01-26 Siemens Healthcare Diagnostics Inc. Devices containing dried reagents for reconstitution as calibration and/or quality control solutions, and methods of production and use thereof
CA3070172A1 (en) 2017-07-18 2019-01-24 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
CN113975378A (zh) * 2021-11-19 2022-01-28 润方（北京）生物医药研究院有限公司 一种聚合血红蛋白在制备治疗缺血性脑卒中药物的应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464284A (en) * 1943-10-18 1949-03-15 Smith Kline French Lab Vasoconstrictor composition
DE1121054B (de) * 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
US3681459A (en) * 1970-10-01 1972-08-01 Armour Pharma Guanidine compounds and use of same
US3925344A (en) * 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
JPS52128205A (en) * 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
DE2617493C3 (de) * 1976-04-22 1979-03-01 The Green Cross Corp., Osaka (Japan) Verwendung von Haptoglobin oder Hämoglobin-Haptoglobin-Komplexen bei der Prophylaxe und Therapie von zerebralen Vasospasmen
US4757052A (en) * 1982-09-03 1988-07-12 Markov Angel K Method of preserving blood
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
USRE34271E (en) * 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5464814A (en) * 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
JP2531661B2 (ja) * 1987-02-25 1996-09-04 味の素株式会社 酸素運搬剤
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5268500A (en) * 1987-06-15 1993-12-07 Montefiore Medical Center Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation
US4994444A (en) * 1987-07-31 1991-02-19 The Trustees Of Columbia In The City Of New York Macromolecules for sealing capillary endothelial junctions
US4988515A (en) * 1988-01-28 1991-01-29 The Regents Of The Univ. Of Calif. Cardioplegic solution
FR2630329B1 (fr) * 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
IL87707A (en) * 1988-09-08 1994-06-24 Technion Inst For Research And Hemoglobin-based blood substitute substantially similar to human blood and method for preparation thereof
IL87708A (en) * 1988-09-08 1994-04-12 Technion Inst For Research And Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof
US5128452A (en) * 1989-04-19 1992-07-07 Baxter International Inc. Process for the production of crosslinked hemoglobin in the presence of sodium tripolyphosphate
DE69027187T2 (de) * 1989-06-15 1996-10-31 Rorer Int Overseas Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen
US5059712A (en) * 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5386014A (en) * 1989-11-22 1995-01-31 Enzon, Inc. Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
ATE136466T1 (de) * 1989-12-29 1996-04-15 Univ Texas Tech Polyhämoglobin durch purinderivate und glutathion stabilisiert
US5439882A (en) * 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
WO1992013875A1 (en) * 1991-02-12 1992-08-20 Texas Tech University Improved blood substitute
US5248785A (en) * 1990-02-12 1993-09-28 Virginia Commonwealth University Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5382680A (en) * 1990-12-07 1995-01-17 The Center For Innovative Technology Allosteric hemoglobin modifier compounds
US5290803A (en) * 1990-02-12 1994-03-01 The Center Of Innovative Technology Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5049695A (en) * 1990-02-12 1991-09-17 Center For Innovative Technology Allosteric hemoglobin modifiers
US5122539A (en) * 1990-02-12 1992-06-16 Center For Innovative Technology Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
CA2036770C (en) * 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
US5248766A (en) * 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
ZW1992A1 (en) * 1991-02-25 1993-09-22 Janssen Pharmaceutica Nv 4-/(2-benzotiazolyl)methylamino/-b-/(3,4-difluorephenoxy)methyl/-1-piperidine ethanol
WO1992020369A1 (en) * 1991-05-14 1992-11-26 Dana Farber Cancer Institute Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5295944A (en) * 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
US5334706A (en) * 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
AU2198592A (en) * 1992-02-20 1993-09-13 Alliance Pharmaceutical Corporation Inhibition of bacterial endotoxin
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
EP0693924B2 (en) * 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
WO1994022482A1 (en) * 1993-03-26 1994-10-13 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
DE4338812A1 (de) * 1993-11-15 1995-05-18 Braun Melsungen Ag Verwendung von Lösungen von vernetztem Hämoglobin zur Bekämpfung des septischen und hämorrhagischen Schocks bei Säugetieren
JPH08511279A (ja) * 1994-03-28 1996-11-26 バクスター、インターナショナル、インコーポレイテッド 血管閉鎖の治療におけるヘモグロビンの治療的使用
DK0815138T3 (da) * 1995-03-23 2002-12-23 Biopure Corp Stabil polymeriseret hæmoglobin-blod-erstatning

Also Published As

Publication number Publication date
EP0767675A1 (en) 1997-04-16
AU5537296A (en) 1996-10-30
NO965247D0 (no) 1996-12-09
WO1996032130A1 (en) 1996-10-17
NO965247L (no) 1996-12-09
ZA962843B (en) 1996-10-11
US5854210A (en) 1998-12-29
EP0767675A4 (en) 1998-08-05
AU693354B2 (en) 1998-06-25
JPH10501823A (ja) 1998-02-17

Similar Documents

Publication Publication Date Title
CA2117891A1 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
AU5309994A (en) Catheter/needle assembly kit and method for administering therapeutic agents to the subarachnoid space
CA2289717A1 (en) Novel therapy for constipation
CA2150937A1 (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
CA2118121A1 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
CA2245661A1 (en) Multiple sclerosis treatment
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
CA2149924A1 (en) Use of phenserine to treat cognitive disorders
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
TW370461B (en) Use of cross-linked hemoglobin in treating subarachnoid hemorrhage
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
CA2139385A1 (en) Products containing g-csf and tnf binding protein
AU4210696A (en) Use of AICA riboside compounds for the treatment and prevention of tissue damage due to decreased blood flow
EP0510063A4 (en) Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
HUP9900147A2 (hu) Terápiás szerek és autoimmun betegségek kezelésére alkalmas gyógyszerkészítmények
CA2045605A1 (en) Treatment of leukocyte dysfunction with gm-csf
CA2144513A1 (en) Morphogen-induced periodontal tissue regeneration
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
AU5201793A (en) Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis
AU5386700A (en) A use of icariin in preparing the medicine for preventing and treating sexual disorder and vasoconstrictive diseases
WO1994004159A3 (en) Treatment of cancer with azt and alkylating or intercalating agents
NZ268039A (en) Use of efaroxan in treating parkinson's disease
James Cidofovir recommended for approval for CMV retinitis